Меню
Идёт набор NCT06561451

Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia

Без фазы С лечением Male Infertility Teratospermia

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: intracytoplasmic sperm injection and artificial oocyte activation, intracytoplasmic sperm injection.
Кому может быть актуально
Состояния в реестре: Male Infertility, Teratospermia. Базовые параметры: 20 лет — 37 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

A Randomized Control Trial to Compare the Live Birth Rate Between Intracytoplasmic Sperm Injection and Artificial Oocyte Activation and Intracytoplasmic Sperm Injection Alone in Patients With Severe Teratospermia

Обзор

The goal of this clinical trial is to compare the live birth rate between intracytoplasmic sperm injection (ICSI) and artificial oocyte activation (AOA) vs intracytoplasmic sperm injection alone in patients with teratospermia. The hypothesis is the live birth rate following ICSI and AOA is significantly higher than that by ICSI alone in patients with teratospermia. This is a randomized controlled trial. Participants will be randomly assigned into one of the two groups: ICSI+AOA group: a single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions. ICSI alone group: a single sperm will be injected within 4 hours after the follicular aspiration.

Вмешательства

  • Процедура intracytoplasmic sperm injection and artificial oocyte activation
    A single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
  • Процедура intracytoplasmic sperm injection
    A single sperm will be injected within 4 hours after the follicular aspiration.

Первичные конечные точки

  • Live birth [Срок оценки: 1 year after embryo transfer]
Вторичные конечные точки (10)
  • Fertilization rate [Срок оценки: 1 day after oocyte retrieval]
  • High-quality embryos on Day 3 [Срок оценки: 3 days after oocyte retrieval]
  • hCG positivity [Срок оценки: 14 days after embryo transfer]
  • Number and grading of embryos/blastocysts [Срок оценки: 6 days after oocyte retrieval]
  • Clinical pregnancy [Срок оценки: 6 weeks of gestation]
  • Ongoing pregnancy [Срок оценки: 12 weeks of gestation]
  • Multiple pregnancy [Срок оценки: 6 weeks of gestation]
  • Cumulative live birth rate (within 6 months after randomization) [Срок оценки: 1.5 years after the randomization]
  • Miscarriage rate [Срок оценки: 22 weeks of pregnancy]
  • Birth weights of the newborns [Срок оценки: 1 year after embryo transfer]

Критерии участия

Критерии включения

  • Age of women 20-37 years at the time of ovarian stimulation for ICSI
  • At least three matured oocytes Severe teratozoospermia: defined as abnormal sperm morphology ranging between 99-100%, including globozoospermia and tapered-head.

Критерии исключения

  • Presence of hydrosalpinx which is not surgically treated
  • Undergoing preimplantation genetic testing
  • Recurrent pregnancy loss (defined as two or more previous spontaneous pregnancy losses)
  • Known uterine abnormality (e.g., uterine congenital malformation; untreated uterine septum, adenomyosis, or submucous myoma; endometrial polyps; or intrauterine adhesions)
  • Abnormal parental karyotyping, or Medical conditions that assisted reproductive technology or pregnancy is contraindicated

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Тройное слепое
Основная цель
Лечение

Центры проведения

Китай · 1 центр
  • ShangHai JIAI Genetics &I VF Institute — Шанхай

Публикации

  • Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992 Jul 4;340(8810):17-8. doi: 10.1016/0140-6736(92)92425-f. PMID 1351601
  • Yeste M, Jones C, Amdani SN, Patel S, Coward K. Oocyte activation deficiency: a role for an oocyte contribution? Hum Reprod Update. 2016 Jan-Feb;22(1):23-47. doi: 10.1093/humupd/dmv040. Epub 2015 Sep 7. PMID 26346057
  • Van Steirteghem AC, Nagy Z, Joris H, Liu J, Staessen C, Smitz J, Wisanto A, Devroey P. High fertilization and implantation rates after intracytoplasmic sperm injection. Hum Reprod. 1993 Jul;8(7):1061-6. doi: 10.1093/oxfordjournals.humrep.a138192. PMID 8408487
  • De Vos A, Van De Velde H, Joris H, Verheyen G, Devroey P, Van Steirteghem A. Influence of individual sperm morphology on fertilization, embryo morphology, and pregnancy outcome of intracytoplasmic sperm injection. Fertil Steril. 2003 Jan;79(1):42-8. doi: 10.1016/s0015-0282(02)04571-5. PMID 12524062
  • Lu YH, Gao HJ, Li BJ, Zheng YM, Ye YH, Qian YL, Xu CM, Huang HF, Jin F. Different sperm sources and parameters can influence intracytoplasmic sperm injection outcomes before embryo implantation. J Zhejiang Univ Sci B. 2012 Jan;13(1):1-10. doi: 10.1631/jzus.B1100216. PMID 22205614
  • Greco E, Scarselli F, Fabozzi G, Colasante A, Zavaglia D, Alviggi E, Litwicka K, Varricchio MT, Minasi MG, Tesarik J. Sperm vacuoles negatively affect outcomes in intracytoplasmic morphologically selected sperm injection in terms of pregnancy, implantation, and live-birth rates. Fertil Steril. 2013 Aug;100(2):379-85. doi: 10.1016/j.fertnstert.2013.04.033. Epub 2013 May 23. PMID 23706334
  • Vanden Meerschaut F, Nikiforaki D, Heindryckx B, De Sutter P. Assisted oocyte activation following ICSI fertilization failure. Reprod Biomed Online. 2014 May;28(5):560-71. doi: 10.1016/j.rbmo.2014.01.008. Epub 2014 Jan 31. PMID 24656559
  • Vanden Meerschaut F, Nikiforaki D, De Gheselle S, Dullaerts V, Van den Abbeel E, Gerris J, Heindryckx B, De Sutter P. Assisted oocyte activation is not beneficial for all patients with a suspected oocyte-related activation deficiency. Hum Reprod. 2012 Jul;27(7):1977-84. doi: 10.1093/humrep/des097. Epub 2012 Apr 4. PMID 22493027

Идентификаторы

NCT: NCT06561451 · JIAI 2024-08

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗